Keymed Biosciences Inc. (HKG: 2162)
Hong Kong
· Delayed Price · Currency is HKD 42.05
+0.20 (0.48%)
Oct 10, 2024, 4:08 PM HKT
Keymed Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -743.07 | -359.36 | -308.12 | -3,887 | -818.58 | -167.51 |
| Depreciation & Amortization | 88.25 | 68.78 | 35.79 | 20.94 | 18.97 | 12.3 |
| Other Amortization | 0.44 | 0.39 | 0.34 | 0.08 | 0.02 | - |
| Loss (Gain) From Sale of Assets | 0.06 | 0.07 | 0.39 | 0.71 | - | - |
| Loss (Gain) From Sale of Investments | - | - | - | - | -0.16 | -0.36 |
| Loss (Gain) on Equity Investments | 4.35 | 4.75 | 9.71 | 0.72 | - | - |
| Stock-Based Compensation | 42.03 | 40.08 | 48.57 | 116.82 | - | - |
| Other Operating Activities | -51.84 | -79.43 | -182.94 | 3,531 | 680.58 | 94.14 |
| Change in Accounts Receivable | -4.5 | -27.09 | 3.98 | -3.98 | - | - |
| Change in Inventory | -3.5 | -11.86 | -28.1 | -9.55 | -3.54 | -3.24 |
| Change in Accounts Payable | -4 | 14.58 | 12.13 | -0.63 | -0.06 | 3.27 |
| Change in Unearned Revenue | -0.21 | - | - | -7 | 10.3 | 2.3 |
| Change in Income Taxes | -2.23 | -1.32 | - | - | - | - |
| Change in Other Net Operating Assets | -34.98 | 46.8 | 6.32 | 23.99 | -6.89 | -9.28 |
| Operating Cash Flow | -709.18 | -303.62 | -401.93 | -214.64 | -119.36 | -68.38 |
| Capital Expenditures | -184.74 | -327.19 | -278.82 | -171.79 | -19.81 | -62.26 |
| Sale (Purchase) of Intangibles | -5.66 | -4.12 | -0.73 | -1.07 | -0.09 | -0.04 |
| Investment in Securities | 10.26 | 700.46 | -575.02 | -1,870 | -104.88 | 3.17 |
| Other Investing Activities | 164.18 | 99.06 | 208.98 | 6.95 | 11.71 | 1.12 |
| Investing Cash Flow | -15.96 | 468.2 | -645.59 | -2,036 | -113.07 | -58.02 |
| Short-Term Debt Issued | - | - | - | - | - | 0.24 |
| Long-Term Debt Issued | - | 360 | 89.95 | - | - | - |
| Total Debt Issued | 524.18 | 360 | 89.95 | - | - | 0.24 |
| Short-Term Debt Repaid | - | -0.23 | -0.33 | -41.82 | -5.61 | - |
| Long-Term Debt Repaid | - | -93.66 | -14.52 | -12.91 | -5.46 | -5.67 |
| Total Debt Repaid | -132.98 | -93.88 | -14.85 | -54.73 | -11.08 | -5.67 |
| Net Debt Issued (Repaid) | 391.2 | 266.12 | 75.1 | -54.73 | -11.08 | -5.43 |
| Issuance of Common Stock | - | - | - | 2,888 | - | - |
| Repurchase of Common Stock | -36.57 | -32.9 | -51.14 | - | - | - |
| Other Financing Activities | -14.64 | -161.09 | -32.03 | -8.5 | 15 | 100 |
| Financing Cash Flow | 339.98 | 72.13 | -8.06 | 3,638 | 7.4 | 505.07 |
| Foreign Exchange Rate Adjustments | -20.13 | 10.25 | 139.03 | -66.65 | -8.17 | 5.14 |
| Net Cash Flow | -405.28 | 246.96 | -916.55 | 1,321 | -233.2 | 383.81 |
| Free Cash Flow | -893.92 | -630.81 | -680.76 | -386.42 | -139.17 | -130.64 |
| Free Cash Flow Margin | -1094.78% | -178.15% | -680.33% | -350.44% | - | - |
| Free Cash Flow Per Share | -3.42 | -2.41 | -2.61 | -2.40 | -2.07 | - |
| Cash Interest Paid | 14.64 | 10.49 | 1.85 | - | - | - |
| Levered Free Cash Flow | -658.76 | -721.97 | -410.26 | -231.71 | -96.12 | - |
| Unlevered Free Cash Flow | -648.27 | -711.19 | -405.01 | -224.75 | -87.18 | - |
| Change in Net Working Capital | 69.55 | 203.22 | -130.16 | -35.57 | -6.84 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.